The benefits observed in these preclinical models, together with an abundance of data supporting the role of impaired brain insulin signaling in AD pathology, suggest that the modification of insulin sensitivity with compounds like RSG could provide therapeutic benefits. The gene discussed is INS; the disease is Alzheimer disease.